Novel coronavirus pneumonia: 30 potentially effective mature drugs + 5 accelerated research and development drugs

Due to the novel coronavirus (2019-nCOV) infection, the CDE of the State Administration of drug supervision has adjusted the registration and acceptance of drugs during the epidemic period, and other fields such as registration, receipt, declaration and consultation will be suspended except for the declaration of special products such as 2019-nCOV infection and pneumonia, and CDE can be contacted at any time In February 8th, the novel coronavirus pneumonia treatment plan was issued by the national health and Health Commission (the fifth version of the revised version) It is clear that there is no effective antiviral treatment In addition to the necessary supportive treatment, patients can try interferon alpha aerosol inhalation, oral lopinavir / ritonavir, or add ribavirin intravenous infusion At the same time, patients should avoid blind or inappropriate use of antibiotics, especially the combination of broad-spectrum antibiotics Lancet novel coronavirus color photos released Novel coronavirus was found in China by the joint research team of Shanghai Institute of Materia Medica of Chinese Academy of Sciences and Shanghai University of science and technology in January 25th It includes 30 kinds of effective drugs, including 12 kinds of anti HIV drugs and other traditional Chinese medicines, such as Polygonum cuspidatum, Radix Sophorae Tonkin The specific list is as follows: Ninhydenavir, xaquinavir, lopinavir, kafezomi, ritonavir, ridcivir or rendisivir, azanavi, darunavir, tiranavir, fosanavir, enzatovir, preytovir, abakavir, bortezomi, etigway, malibavir or mambavir, retgevir, montelukast, deoxyturkish rhubarb, polydatin, Shandou Gen chalcone , disulfiram, Carmofur, shikonin, ebse, tideglusib, PX-12, tdzd-8, cyclosporin A, cinnamyl thiamine In addition, there are many enterprises at home and abroad trying to cooperate in different degrees to seek more effective solutions On February 5, the clinical trial for 2019-ncov of Gilead radcivir was launched in Wuhan As of February 7, the program was adjusted for many times Professor Zhao Jianping, an expert of Hubei medical treatment group, released a new clinical grouping program, which is now more inclined to severe patients The ratio of the former treatment group to the control group was 1:1, and the adjusted treatment group to the control group was 2:1, which means that the subjects had a 66% probability of receiving radcivir treatment On January 30, inovio pharmaceuticals, Inc (nsdq: iNO) and Beijing Aidi Weixin Biotechnology Co., Ltd jointly accelerated the development of 2019-ncov vaccine ino-4800 in China Innovio recently announced that the epidemic prevention Innovation Alliance (CEPI) has provided up to $9 million in funding to innovio to support innovio to pass the phase I human trial of ino-4800 in the United States to assess the safety and immunogenicity of the vaccine The cooperation aims to conduct a phase I trial in China with the technology of etivix and cooperate with the clinical development work of inovio in the United States Inovio and idevicin will also work together to raise more funds, and further cooperate with China's large vaccine companies to improve the speed of testing ino-4800 in the future On February 2, Guanhao Biotechnology Co., Ltd (hereinafter referred to as "Guanhao biotechnology", securities code: 300238) and the joint-stock company ZY therapeutics Inc (hereinafter referred to as "ZY") signed a framework agreement on cooperation intention of nucleic acid vaccine project to jointly carry out the research and clinical project of new type pneumonia coronavirus mRNA vaccine (z-vaccirna) On February 7, shutaishen (Beijing) biopharmaceutical Co., Ltd (hereinafter referred to as "shutaishen", securities code: 300204) received the approval for clinical trials of drugs, allowing its bdb-001 injection to carry out clinical trials aimed at reducing the incidence of severe pneumonia and acute respiratory distress syndrome in 2019 ncov infected patients;